©istock.com/Andrea Obzerova
Interdisciplinary CompetenceMolecular Diagnostics
Know how in the analysis of genetic material.
For the benefit of patients.

IllnessCone-rod dystrophy / macular dystrophy, retinitis pigmentosa; differential diagnosis [exp. panel]

Summary

Short information

Comprehensive differential diagnostic panel for Cone-rod dystrophy/ macular dstrophy containing 11 core candidate genes and altogether 120 curated genes according to the clinical signs

ID
ZP0010
Number of genes
95 Accredited laboratory test
Examined sequence length
41,6 kb (Core-/Core-canditate-Genes)
230,3 kb (Extended panel: incl. additional genes)
Analysis Duration
on request
Test material
  • EDTA-anticoagulated blood (3-5 ml)
Diagnostic indications

NGS +

 

Gene panel

Selected genes

NameExon Length (bp)OMIM-GReferenz-Seq.Heredity
ABCA46822NM_000350.3AR
BEST11758NM_004183.4AD, AR
CDHR12580NM_033100.4AR
CNGA32085NM_001298.3AR
PDE6C2577NM_006204.4AR
PROM12598NM_006017.3AD, AR
PRPH21041NM_000322.5AD, AR, digenisch
RP21053NM_006915.3XLR
RPE651602NM_000329.3AD, AR
RPGRIP13861NM_020366.4AR
USH2A15609NM_206933.4AR
ADAM92460NM_003816.3AR
AGBL52740NM_001035507.3AR
AIPL11155NM_014336.5AD, AR
ARHGEF183598
  • No OMIM-Gs linked
NM_001130955.2AR
ARL2BP492NM_012106.4AR
ARL6561NM_177976.3AR
C1QTNF5732NM_015645.5AD
C2orf713869
  • No OMIM-Gs linked
NM_004928.3AR
CABP4828NM_145200.5AR
CACNA1F5934NM_005183.4XLR
CACNA2D43414NM_172364.5AR
CDH32490NM_001793.6AR
CEP2907440NM_025114.4AR
CEP782216NM_001098802.3AR
CERKL1677NM_001030311.3AR
CFAP4101507NM_004928.3AR
CFAP418624NM_177965.4AR
CFH3696NM_000186.4AD
CLRN1699NM_174878.3AR
CNGA12073NM_000087.5AD, AR
CNGB1900NM_001135639.2AR
CNGB32430NM_019098.5AR
CRB14221NM_201253.3AR
CRX900NM_000554.6AD
CWC271883NM_005869.4AR
DHDDS900NM_001243564.2AR
EFEMP11482NM_001039348.3AD
ELOVL4945NM_022726.4AD
EYS9435NM_001142800.2AR
FAM161A2151NM_001201543.2AR
FLVCR11668NM_014053.4AR
GUCA1A606NM_001384910.1AD
GUCA1B603NM_002098.6AD
GUCY2D3312NM_000180.4AD, AR
HGSNAT1908NM_152419.3AR
IDH3A1248
  • No OMIM-Gs linked
NM_005530.3AR
IDH3B1158NM_006899.5AR
IFT1404389NM_014714.4AR
IMPDH11800NM_000883.4AD
IMPG23726NM_016247.4AD, AR
KCNV21638NM_133497.4AR
KIZ1712NM_001163022.3AR
KLHL71761NM_001031710.3AD
MAK1752NM_001242385.2AR
MERTK3000NM_006343.3AR
MFSD81557NM_152778.3AR
NR2E31234NM_014249.4AD, AR
NRL714NM_006177.5AD, AR
OFD13039NM_003611.3XL
OTX2870NM_172337.3AD
PCYT1A1104NM_005017.4AR
PDE6A2583NM_000440.3AR
PDE6B2565NM_000283.4AD, AR
PDE6G264NM_002602.4AR
PRCD165NM_001077620.3AR
PRPF32052NM_004698.4AD
PRPF311500NM_015629.4AD
PRPF41566NM_001244926.2AD
PRPF62826NM_012469.4AD
PRPF87008NM_006445.4AD
RAB28663NM_004249.4AR
RAX2555NM_032753.4AD
RBP33744NM_002900.3AR
RBP4606NM_006744.4AD, AR
RCBTB11596NM_018191.4AD, AR
REEP6560NM_138393.4AR
RGS92025NM_003835.4AR
RHO1047NM_000539.3AD, AR
RLBP1954NM_000326.5AD, AR
RP16471NM_006269.2AD, AR
RP1L17203NM_178857.6AR
RP9666NM_203288.2AD
RPGR2448NM_000328.3XL
SAG1218NM_000541.5AD, AR
SCAPER4203NM_020843.4AR
SEMA4A2286NM_022367.4AR
SNRNP2006411NM_014014.5AD
SPATA71704NM_001040428.4AR
TIMP3636NM_000362.5AD
TOPORS3138NM_005802.5AD
TTC81518NM_198309.3AR
TTLL53846NM_015072.5AR
TULP11629NM_003322.6AR
UNC119723NM_005148.4AD

Informations about the disease

Clinical Comment

Inherited retinal dystrophies (RDs) are a group of diseases that can be syndromic or non-syndromic. The visual impairment can range from poor peripheral or night vision to complete blindness, the severity usually increasing with age. RDs can be divided into groups according to the affected photoreceptors and the manifestations or degree of atrophy within the retina. RD groups include rod-dominated diseases, cone-dominated diseases and generalized retinal degenerations involving both rod and cone photoreceptors. Among rod and cone dystrophies, progressive degenerative forms including retinitis pigmentosa can be distinguished as well as stationary forms known as congenital stationary night blindness. RDs thus occur due to abnormalities in the cellular structures of the retina as well as defects in the phototransduction cascade and visual cycle biochemistry. RD occurs during the entire life span from birth until after the age of 60. All classical transmission patterns are observed as well as rarely digenic heredity. Sometimes there is incomplete penetrance and often different clinical expression. An inconspicuous genetic finding does not mean a reliable exclusion of the suspected clinical diagnosis, since the molecular genetic diagnostic yield is incomplete (>50-65%).

Reference: https://www.ncbi.nlm.nih.gov/books/NBK1417/

 

Synonyms
  • Alias included: Retinitis pigmentosa
  • Alias: Cone-rod dystrophy; CORD
  • Alias: Macular dystrophy
  • Allelic Senior-Loken syndrome 6 (CEP290)
  • Allelic: Aland Island eye disease (CACNA1F)
  • Allelic: Bardet-Biedl syndrome 21 (C8orf37)
  • Allelic: Basal laminar drusen (CFH)
  • Allelic: Bestrophinopathy, AR (BEST1)
  • Allelic: Bradyopsia (RGS9)
  • Allelic: Bradyopsia (RGS9BP)
  • Allelic: Cerebellar dysfunction, impaired intellect. develop. + hypogonadotr. hypogonadism (PRDM13)
  • Allelic: Ceroid lipofuscinosis, neuronal, 7 (MFSD8)
  • Allelic: Choroidal dystrophy, central areolar 2 (PRPH2)
  • Allelic: Complement factor B deficiency (CFB)
  • Allelic: Complement factor H deficiency (CFH)
  • Allelic: Cutis laxa, AD 2 (FBLN5)
  • Allelic: Cutis laxa, AR, type IA (FBLN5)
  • Allelic: Dementia, familial British (ITM2B)
  • Allelic: Dementia, familial Danish (ITM2B)
  • Allelic: Fundus flavimaculatus (ABCA4)
  • Allelic: Hemolytic uremic syndrome, atypical, susceptibility to, 1 (CFH)
  • Allelic: Hemolytic uremic syndrome, atypical, susceptibility to, 4 (CFB)
  • Allelic: Ichthyosis, spastic quadriplegia + mental retardation (ELOVL4)
  • Allelic: Immunodeficiency 13 (UNC119)
  • Allelic: Joubert syndrome 5 (CEP290)
  • Allelic: Leber congenital amaurosis 10 (CEP290)
  • Allelic: Leber congenital amaurosis 18 (PRPH2)
  • Allelic: Leber congenital amaurosis 4 (AIPL1)
  • Allelic: Leber congenital amaurosis 6 (RPGRIP1)
  • Allelic: Leber congenital amaurosis 7 (CRX)
  • Allelic: Meckel syndrome 4 (CEP290)
  • Allelic: Microcornea, rod-cone dystrophy, cataract + posterior staphyloma (BEST1)
  • Allelic: Microphthalmia, isolated, with coloboma 10 (RBP4)
  • Allelic: Night blindness, congenital stationary (incomplete), 2A, XL (CACNA1F)
  • Allelic: PERCHING syndrome (KLHL7)
  • Allelic: Retinitis punctata albescens (PRPH2)
  • Allelic: Retinoschisis (RS1)
  • Allelic: Spinocerebellar ataxia 34 (ELOVL4)
  • Allelic: Spondylometaphyseal dysplasia, axial (CFAP410)
  • Allelic: Vitreoretinochoroidopathy (BEST1)
  • Achromatopsia 3 (CNGB3)
  • Achromatopsia 4 (GNAT2)
  • Achromatopsia 7 (ATF6)
  • Achromatopsia, Cone + Cone-rod dystrophy [panelapp] (GNAT2)
  • Achromatopsia, Cone + Cone-rod dystrophy [panelapp] (RDH5)
  • Ataxia, posterior column, with retinitis pigmentosa (FLVCR1)
  • Bardet-Biedl syndrome 14 (CEP290)
  • Bothnia retinal dystrophy (RLBP1)
  • Cone dystrophy 3 (GUCA1A)
  • Cone dystrophy 4 (PDE6C)
  • Cone dystrophy [MONDO:0000455] (IRX1)
  • Cone-rod dystrophy (AIPL1)
  • Cone-rod dystrophy (UNC119)
  • Cone-rod dystrophy + hearing loss (CEP78)
  • Cone-rod dystrophy 10 (SEMA4A)
  • Cone-rod dystrophy 11 (RAX2)
  • Cone-rod dystrophy 12 (PROM1)
  • Cone-rod dystrophy 13 (RPGRIP1)
  • Cone-rod dystrophy 14 (GUCA1A)
  • Cone-rod dystrophy 15 (CDHR1)
  • Cone-rod dystrophy 16 (C8orf37 syn. CFAP418)
  • Cone-rod dystrophy 16 (C8orf37)
  • Cone-rod dystrophy 18 (RAB28)
  • Cone-rod dystrophy 19 (TTLL5)
  • Cone-rod dystrophy 20 (POC1B)
  • Cone-rod dystrophy 21 (DRAM2)
  • Cone-rod dystrophy 22 (TLCD3B)
  • Cone-rod dystrophy 3 (ABCA4)
  • Cone-rod dystrophy 5 (PITPNM3)
  • Cone-rod dystrophy 7 (RIMS1)
  • Cone-rod dystrophy 9 (ADAM9)
  • Cone-rod dystrophy [panelapp] (GNAT2)
  • Cone-rod dystrophy and hearing loss 2 (CEP250)
  • Cone-rod dystrophy, XL, 1 (RPGR)
  • Cone-rod dystrophy, XL, 3 (CACNA1F)
  • Cone-rod retinal dystrophy-2 (CRX)
  • Cone-rod synaptic disorder syndrome, congenital nonprogressive (RIMS2)
  • Cone-rod synaptic disorder, congenital nonprogressive (CABP4)
  • Developmental macular + foveal dystrophy [panelapp] (RS1)
  • Developmental macular + foveal dystrophy; foveal hypoplasia in albinism [panelapp] (GPR143)
  • Doyne honeycomb degeneration of retina (EFEMP1)
  • Ectodermal dysplasia, ectrodactyly + macular dystrophy (CDH3)
  • Fundus albipunctatus (RDH5)
  • Hypotrichosis, congenital, with juvenile macular dystrophy (CDH3)
  • Intellectual developmental disorder + retinitis pigmentosa (SCAPER)
  • Jalili syndrome (CNNM4)
  • Jalili syndrome [cone-rod dystrophy + amelogenesis imperfecta] (CNNM4)
  • Joubert syndrome 35 (ARL3)
  • Leber congenital amaurosis 13 (RDH12)
  • Macular degeneration, XL atrophic (RPGR)
  • Macular degeneration, age-related, 1 (HMCN1)
  • Macular degeneration, age-related, 14, reduced risk of (CFB)
  • Macular degeneration, age-related, 2 (ABCA4)
  • Macular degeneration, age-related, 3 (FBLN5)
  • Macular degeneration, age-related, 4 (CFH)
  • Macular degeneration, age-related, 6 (RAX2)
  • Macular degeneration, juvenile (CNGB3)
  • Macular dystrophy with central cone involvement (MFSD8)
  • Macular dystrophy, patterned, 1 (PRPH2)
  • Macular dystrophy, patterned, 2 (CTNNA1)
  • Macular dystrophy, retinal, 2 (PROM1)
  • Macular dystrophy, vitelliform, 2 (BEST1)
  • Macular dystrophy, vitelliform, 3 (PRPH2)
  • Macular dystrophy, vitelliform, 4 (IMPG1)
  • Macular dystrophy, vitelliform, 5 (IMPG2)
  • Macular dystrophy/Degeneration/Stargardt disease [panelapp] (CNGB3)
  • Macular dystrophy/Degeneration/Stargardt disease [panelapp] (RDH12)
  • Microcephaly + chorioretinopathy, AR, 1 (TUBGCP6)
  • Microcephaly + chorioretinopathy, AR, 2 (PLK4)
  • Microcephaly + chorioretinopathy, AR, 3 (TUBGCP4)
  • Neuropathy, hereditary, with/-out age-related macular degeneration (FBLN5)
  • Newfoundland rod-cone dystrophy (RLBP1)
  • North Carolina macular dystrophy [MONDO:0007630] (PRDM13)
  • Nystagmus 6, congenital, XL (GPR143)
  • Occult macular dystrophy (RP1L1)
  • Ocular albinism, type I, Nettleship-Falls type (GPR143)
  • Retinal cone dystrophy 3 (PDE6H)
  • Retinal cone dystrophy 3B (KCNV2)
  • Retinal cone dystrophy 4 (CACNA2D4)
  • Retinal degeneration, AR, clumped pigment type (NRL)
  • Retinal degeneration, late-onset, AD (C1QTNF5)
  • Retinal dystrophy with inner retinal dysfunction + ganglion cell abnormalities (ITM2B)
  • Retinal dystrophy with macular staphyloma (C21orf2)
  • Retinal dystrophy with macular staphyloma (CFAP410)
  • Retinal dystrophy with/-out extraocular anomalies (RCBTB1)
  • Retinal dystrophy, early-onset severe (ABCA4)
  • Retinal dystrophy, early-onset, with/-out pituitary dysfunction (OTX2)
  • Retinal dystrophy, iris coloboma + comedogenic acne syndrome (RBP4)
  • Retinitis pigmentosa 1 (RP1)
  • Retinitis pigmentosa 10 (IMPDH1)
  • Retinitis pigmentosa 11 (PRPF31)
  • Retinitis pigmentosa 12 (CRB1)
  • Retinitis pigmentosa 13 (PRPF8)
  • Retinitis pigmentosa 14 (TULP1)
  • Retinitis pigmentosa 18 (PRPF3)
  • Retinitis pigmentosa 19 (ABCA4)
  • Retinitis pigmentosa 2 (RP2)
  • Retinitis pigmentosa 20 (RPE65)
  • Retinitis pigmentosa 23 (OFD1)
  • Retinitis pigmentosa 25 (EYS)
  • Retinitis pigmentosa 26 (CERKL)
  • Retinitis pigmentosa 27 (NRL)
  • Retinitis pigmentosa 28 (FAM161A)
  • Retinitis pigmentosa 3 (RPGR)
  • Retinitis pigmentosa 31 (TOPORS)
  • Retinitis pigmentosa 33 (SNRNP200)
  • Retinitis pigmentosa 35 (SEMA4A)
  • Retinitis pigmentosa 36 (PRCD)
  • Retinitis pigmentosa 37 (NR2E3)
  • Retinitis pigmentosa 38 (MERTK)
  • Retinitis pigmentosa 4, AD/AR (RHO)
  • Retinitis pigmentosa 40 (PDE6B)
  • Retinitis pigmentosa 41 (PROM1)
  • Retinitis pigmentosa 42 (KLHL7)
  • Retinitis pigmentosa 43 (PDE6A)
  • Retinitis pigmentosa 45 (CNGB1)
  • Retinitis pigmentosa 46 (IDH3B)
  • Retinitis pigmentosa 47 (SAG)
  • Retinitis pigmentosa 48 (GUCA1B)
  • Retinitis pigmentosa 49 (CNGA1)
  • Retinitis pigmentosa 50 (BEST1)
  • Retinitis pigmentosa 51 (TTC8)
  • Retinitis pigmentosa 54 (C2orf71)
  • Retinitis pigmentosa 55 (ARL6)
  • Retinitis pigmentosa 56 (IMPG2)
  • Retinitis pigmentosa 57 (PDE6G)
  • Retinitis pigmentosa 59 (DHDDS)
  • Retinitis pigmentosa 60 (PRPF6)
  • Retinitis pigmentosa 61 (CLRN1)
  • Retinitis pigmentosa 62 (MAK)
  • Retinitis pigmentosa 64 (C8orf37 syn. CFAP418)
  • Retinitis pigmentosa 64 (C8orf37)
  • Retinitis pigmentosa 65 (CDHR1)
  • Retinitis pigmentosa 66 (RBP3)
  • Retinitis pigmentosa 69 (KIZ)
  • Retinitis pigmentosa 7 + digenic form (PRPH2)
  • Retinitis pigmentosa 70 (PRPF4)
  • Retinitis pigmentosa 73 (HGSNAT)
  • Retinitis pigmentosa 75 (AGBL5)
  • Retinitis pigmentosa 77 (REEP6)
  • Retinitis pigmentosa 78 (ARHGEF18)
  • Retinitis pigmentosa 80 (IFT140)
  • Retinitis pigmentosa 83 (ARL3)
  • Retinitis pigmentosa 87 with choroidal involvement (RPE65)
  • Retinitis pigmentosa 88 (RP1L1)
  • Retinitis pigmentosa 9 (RP9)
  • Retinitis pigmentosa 90 (IDH3A)
  • Retinitis pigmentosa 91 (IMPG1)
  • Retinitis pigmentosa [panelapp] (RDH12)
  • Retinitis pigmentosa with/-out situs inversus (ARL2BP)
  • Retinitis pigmentosa with/-out skeletal anomalies (CWC27)
  • Retinitis pigmentosa, XL + sinorespiratory infections, with/-out deafness (RPGR)
  • Retinitis pigmentosa, concentric (BEST1)
  • Retinitis pigmentosa, juvenile (AIPL1)
  • Retinitis pigmentosa, juvenile, AR (SPATA7)
  • Sorsby fundus dystrophy (TIMP3)
  • Spondylometaphyseal dysplasia with cone-rod dystrophy (PCYT1A)
  • Stargardt disease 1 (ABCA4)
  • Stargardt disease 3 (ELOVL4)
  • Stargardt disease 4 (PROM1)
Heredity, heredity patterns etc.
  • AD
  • AR
  • XL
  • XLR
  • digenisch
OMIM-Ps
  • Multiple OMIM-Ps
ICD10 Code

Bioinformatics and clinical interpretation

Test-Stärken

  • DAkkS-akkreditiertes Labor
  • EU-Richtlinie für IVD in Umsetzung
  • Qualitäts-kontrolliert arbeitendes Personal
  • Leistungsstarke Sequenzierungstechnologien, fortschrittliche Target-Anreicherungsmethoden und Präzisions-Bioinformatik-Pipelines sorgen für überragende analytische Leistung
  • Sorgfältige Kuratierung klinisch relevanter und wissenschaftlich begründeter Gen-Panels
  • eine Vielzahl nicht Protein-kodierender Varianten, die in unseren klinischen NGS-Tests mit erfasst werden
  • unser strenges Variantenklassifizierungsschema nach ACMG-Kriterien
  • unser systematischer klinischer Interpretations-Workflow mit proprietärer Software ermöglicht die genaue und nachvollziehbare Verarbeitung von NGS-Daten
  • unsere umfassenden klinischen Aussagen

Testeinschränkungen

  • Gene mit eingeschränkter Abdeckung werden gekennzeichnet
  • Gene mit kompletten oder partiellen Duplikationen werden gekennzeichnet
  • es wird angenommen, dass ein Gen suboptimal abgedeckt ist, wenn >90% der Nukleotide des Gens bei einem Mapping-Qualitätsfaktor von >20 (MQ>20) nicht abgedeckt sind
  • die Sensitivität der Diagnostik zur Erkennung von Varianten mit genannten Testeinschränkungen ist möglicherweise begrenzt bei:
  • Gen-Konversionen
  • komplexe Inversionen
  • Balancierte Translokationen
  • Mitochondriale Varianten
  • Repeat-Expansionen, sofern nicht anders dokumentiert
  • nicht kodierende Varianten, die Krankheiten verursachen, die von diesem Panel nicht mit abgedeckt werden
  • niedriger Mosaik-Status
  • Repeat-Blöcke von Mononukleotiden
  • Indels >50bp (Insertionen-Deletionen)
  • Deletionen oder Duplikationen einzelner Exons
  • Varianten innerhalb von Pseudogenen
  • die analytische Sensitivität kann geringer ausfallen werden, wenn die DNA nicht von amedes genetics extrahiert wurde

Laboratory requirement

  • Die in grün gezeigten Gene sind kuratiert und werden als Gen-Panel untersucht. Eine Erweiterung des Panels (blau gezeigte Gene, jeweils ebenfalls kuratiert) kann auf Anfrage erfolgen. Sofern unter "Erweitertes Panel" ein Minuszeichen angezeigt wird, sind nur Core-/Basis-Gene verfügbar.

  • Für die Anforderung einer genetischen Untersuchung senden Sie uns bitte die Krankheits-ID auf einem Überweisungsschein. Bitte die Material-Angabe beachten.

  • Für privat versicherte Patienten empfehlen wir einen Antrag auf Kostenübernahme bei der Krankenversicherung.

  • Die Untersuchung wird auch für Selbstzahler angeboten.